Community Pharmacy England News

- 21ST AUGUST 2025
- 0 COMMENTS
Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets (Chanelle Medical Unlimited Company)
MHRA Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets (Chanelle Medical Unlimited Company) Drug alert number: EL(25)A/41 Date issued: 21 August 2025 Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on certain batches of Fexofenadine Hydrochloride 120mg film-coated
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 19TH AUGUST 2025
- 0 COMMENTS
August 2025 Price Concessions 1st Update
The Department of Health and Social Care (DHSC) has today (19/08/2025) confirmed the following initial list of price concessions for August 2025: Drug Pack size Price concession Alfuzosin 2.5mg tablets 60 £7.22 Clarithromycin 250mg/5ml oral suspension 70 £10.52 Cyclizine 50mg/1ml solution for injection ampoules 5 £4.01 Dutasteride 500microgram capsules 30 £2.88 Ibuprofen 600mg tablets 84 £9.38
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 14TH AUGUST 2025
- 0 COMMENTS
MHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited)
MHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited) Date issued: 14 August 2025 Drug Alert Number: EL(25)A/40 Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information. DMRC reference number: DMRC-35838218 Marketing Authorisation
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 14TH AUGUST 2025
- 0 COMMENTS
Dapagliflozin tablets – changes to reimbursement from September 2025
Dapagliflozin 5mg and 10mg tablets will be moving from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. Currently, all branded and generically written prescriptions
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 12TH AUGUST 2025
- 0 COMMENTS
DHSC outlines work to improve medicines supply
The Department of Health and Social Care (DHSC) has published details of its ongoing work and plans to improve the management of medicines supply issues. This includes a commitment to consulting on the introduction of pharmacist flexibilities to supply alternatives when a medicine is in short supply. The new policy paper, Managing a robust and
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 11TH AUGUST 2025
- 0 COMMENTS
Rollout of prescription status info in the NHS App continues
The National Patient Prescription Tracking Service (NPPTS) enables patients to access and track their prescriptions online through the NHS App or their NHS account (by logging in on the NHS website). NPPTS is a feature of the Electronic Prescription Service (EPS) that utilises a combination of Spine and Pharmacy IT supplier systems’ information to provide item and
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 11TH AUGUST 2025
- 0 COMMENTS
Medicines not covered by the HRT PPC
The NHS Business Services Authority (NHSBSA) has seen an increase in the number of prescriptions from patients using the “HRT only prescription prepayment certificate” prescription charge exemption category for products that are not covered by the HRT Prescription Prepayment Certificate (HRT PPC). In the 12 months between June 2024 and May 2025, the NHSBSA received over 200k
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 8TH AUGUST 2025
- 0 COMMENTS
Sector workshop findings to inform Committee discussions
Opinions from pharmacy owners and LPCs across the country are being compiled, alongside inputs from national pharmacy organisations and results from ongoing sector polling, to inform Community Pharmacy England Committee discussions on negotiating priorities for 2026/27. The Committee will consider all inputs, alongside Community Pharmacy England’s own analysis, to inform positioning and objectives for the
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 8TH AUGUST 2025
- 0 COMMENTS
Improved price concessions for July 2025
Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the following July 2025 concessionary prices: Drug Pack size Previous price concession for July 2025 New price concession for July 2025 Fexofenadine 180mg tablets 30 £2.31 £4.10 Pioglitazone 45mg tablets 28 £25.25
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News
- 7TH AUGUST 2025
- 0 COMMENTS
Class 4 Medicines Defect Notification: Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution, Zydus Pharmaceuticals UK Ltd
MHRA Class 4 Medicines Defect Notification: Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution, Zydus Pharmaceuticals UK Ltd Drug alert number: EL(25)A/39 Date issued: 07 August 2025 Zydus Pharmaceuticals UK LTD has informed the MHRA that there is an error on the artwork for the outer carton and Patient Information Leaflet (PIL) of Topiramate Zydus Pharmaceuticals UK
Read more
- Middlesex Pharmaceutical Group
- Community Pharmacy England News

Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets (Chanelle Medical Unlimited Company)

August 2025 Price Concessions 1st Update

MHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited)

Dapagliflozin tablets – changes to reimbursement from September 2025

DHSC outlines work to improve medicines supply

Rollout of prescription status info in the NHS App continues

Medicines not covered by the HRT PPC

Sector workshop findings to inform Committee discussions

Improved price concessions for July 2025

Class 4 Medicines Defect Notification: Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution, Zydus Pharmaceuticals UK Ltd

Get in Touch

Working together with key healthcare stakeholders, local councils and other healthcare organisations as necessary to ensure that the provision of pharmaceutical services continues to be an integral part of Health and Social Care